Saniona minskar sin ägarandel i Scandion Oncology till under 5 procent som ett resultat av Scandions framgångsrika företrädesemission
December 16, 2020 02:00 ET
|
Saniona AB
PRESSMEDDELANDE 16 december 2020 Saniona minskar sin ägarandel i Scandion Oncology till under 5 procent som ett resultat av Scandions framgångsrika företrädesemission Saniona (OMX: SANION), ett...
Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5% Following Scandion’s Successful Rights Issue
December 16, 2020 02:00 ET
|
Saniona AB
PRESS RELEASE December 16, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the reduction of its ownership stake in Scandion Oncology...
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
November 30, 2020 16:05 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...
Saniona publicerar sin delårsrapport för det tredje kvartalet 2020
November 30, 2020 02:00 ET
|
Saniona AB
PRESSMEDDELANDE 30 november 2020 Finansiella nyckeltal Jan - sep 2020 (jan - sep 2019) Nettoomsättningen uppgick till 4,6 MSEK (2,7)EBIT uppgick till -97,0 MSEK (-75,8)Periodens...
Saniona publishes its interim report for the third quarter 2020
November 30, 2020 02:00 ET
|
Saniona AB
PRESS RELEASE November 30, 2020 Financial highlights Jan - Sep 2020 (Jan - Sep 2019) Net revenues were SEK 4.6 M (2.7 M)EBIT was SEK -97.0 M (-75.8 M)Net profit/loss was SEK -117.3 M (-72.3...
Saniona rapporterar positiva topline-resultat från den öppna förlängningen av Fas 2-studien med Tesomet mot hypotalamisk fetma
November 23, 2020 11:00 ET
|
Saniona AB
PRESSMEDDELANDE 23 november 2020 Tesomet tolererades väl av patienterna med hypotalamisk fetma under hela den 48 veckor långa studien (24 veckor dubbelblind del följt av 24 veckor öppen...
Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity
November 23, 2020 11:00 ET
|
Saniona AB
PRESS RELEASE November 23, 2020 Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
November 16, 2020 08:00 ET
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
November 12, 2020 06:00 ET
|
Inozyme Pharma Inc.
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency – – Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment...
Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs
November 09, 2020 06:00 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal...